Virpax Pharmaceuticals extends collaboration with NIH for pain management drug development
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX), a company focused on innovative pharmaceutical solutions for pain management, announced the extension of its cooperative research and development agreement ... Read More
Thermo Fisher Scientific and NCI launch myeloMATCH trial to advance AML and MDS treatment
In a significant advancement in cancer treatment, Thermo Fisher Scientific Inc. (NYSE: TMO) has partnered with the National Cancer Institute (NCI), a component of the ... Read More
RevBio secures NIH grant for game-changing TETRANITE Technology
RevBio, Inc., revealed that it has secured a substantial grant of up to $3.4 million, to be disbursed over the next three years, from the ... Read More
BITT secures NIH funding for pioneering Sjögren’s syndrome treatment
Boston Immune Technologies and Therapeutics, Inc. (BITT), a leading clinical-stage biotechnology firm specializing in tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, has received a ... Read More
US NIH stops ACTIV-2 phase 3 trial of Covid-19 drug candidate SAB-185
SAB Biotherapeutics said that the US National Institutes of Health (NIH) is discontinuing the phase 3 ACTIV-2 trial of the company’s SAB-185 for the treatment ... Read More
Bharat Biotech reports positive Covaxin phase 3 results with 77.8% efficacy
Covaxin phase 3 results : Bharat Biotech, an Indian biotech company, said that Covaxin, its whole virion inactivated vaccine against SARS-CoV2, has demonstrated efficacy of ... Read More
Sound Pharmaceuticals gets NIH grant for Covid-19 candidate SPI-1005
Sound Pharmaceuticals has secured a grant of $3.1 million for supporting the evaluation of its COVID-19 treatment candidate SPI-1005 in two phase 2 clinical trials ... Read More
Cancer Targeted Technology gets NIH grant to support CTT1403 trial
Cancer Targeted Technology (CTT), a Seattle-based biotech company, has secured a grant of $1.44 million from the US National Institutes of Health (NIH) to support ... Read More
Coronavirus vaccine trial results : Moderna mRNA-1273 shows early promise
Moderna said that mRNA-1273, its novel coronavirus vaccine candidate, has delivered positive interim data in a phase 1 clinical trial by eliciting neutralizing antibody titer ... Read More
Coronavirus vaccine trial : Moderna doses first subject with mRNA-1273 in phase 1 trial
Coronavirus vaccine trial : US biotech company Moderna has dosed the first participant in the phase 1 study of mRNA-1273, its mRNA vaccine against the ... Read More